MiR‐128 regulation of glucose metabolism and cell proliferation in triple‐negative breast cancer.
Published: 8th November 2017
Authors: M. Xiao, C. Lou, H. Xiao, Y. Yang, X. Cai, C. Li et al.
Triple‐negative breast cancer (TNBC) is prone to metastasis and has a poor prognosis, with lower survival rates than other breast cancer subtypes. MicroRNAs have recently emerged as powerful regulators of cancer processes and become a promising target in cancer therapy.
Expression of miR‐128 was examined in invasive ductal breast cancer, and its relationship with clinicopathological features analysed. A series of
A cohort of 110 women with TNBC and 117 with non‐TNBC were included in the study. In multivariable Cox regression analysis, overall and disease‐free survival were significantly associated with lymph node metastasis, histological grade and molecular subtype. Subgroup analysis showed that low expression of miR‐128 correlated with shorter overall and disease‐free survival in TNBC (
MiR‐128 might be a prognostic marker and possible molecular target for therapy in patients with TNBC.Read more
You may also be interested in
International validation of the European Organisation for Research and Treatment of Cancer QLQ‐BRECON23 quality‐of‐life questionnaire for women undergoing breast reconstruction.
Authors: Z. E. Winters, M. Afzal, C. Rutherford, B. Holzner, G. Rumpold, R. A. da Costa Vieira et al.
Notes: Useful tool
Axillary tumour burden in women with a fine‐needle aspiration/core biopsy‐proven positive node on ultrasonography compared to women with a positive sentinel node. BJS 2017; 104: 1811-1815.
Authors: P. Lloyd, E. Theophilidou, R. G. Newcombe, L. Pugh, A. Goyal
Notes: Axillary ultrasound can detect low‐volume metastases
Superparamagnetic iron oxide nanoparticles as the sole method for sentinel node biopsy detection in patients with breast cancer. BJS 2017; 104: 1675-1685.
Authors: A. Karakatsanis, K. Daskalakis, P. Stålberg, H. Olofsson, Y. Andersson, S. Eriksson et al.
Notes: Simplifies logistics
Authors: M. Ahmed, M. Douek
Risk of death from breast cancer after treatment for ductal carcinoma in situ. BJS 2017; 104: 1506-1513.
Authors: C. Wadsten, H. Garmo, I. Fredriksson, M. Sund, F. Wärnberg
Notes: Rare, but worse for large tumours and uncertain margins
Improved prognosis of young patients with breast cancer undergoing breast‐conserving surgery. BJS 2017; 104: 1802-1810.
Authors: E. Botteri, P. Veronesi, J. Vila, N. Rotmensz, V. Galimberti, M. V. Thomazini et al.
Notes: Molecular subtype matters most
Authors: R. N. Pedersen, K. Bhaskaran, U. Heide‐Jørgensen, M. Nørgaard, P. M. Christiansen, N. Kroman et al.
Notes: No correlation
Nomograms for preoperative prediction of axillary nodal status in breast cancer. BJS 2017; 104: 1494-1505.
Authors: L. Dihge, P.‐O. Bendahl, L. Rydén
Notes: Defines need for staging?
Authors: J. R. Benson, S. K. Down
Authors: R. V. Dave, R. Millican‐Slater, D. Dodwell, K. Horgan, N. Sharma
Notes: Mid‐neoadjuvant chemotherapy MRI useful
Combined PET–CT and axillary lymph node marking with radioactive iodine seeds (MARI procedure) for tailored axillary treatment in node‐positive breast cancer after neoadjuvant therapy. BJS 2017; 104: 1188-1196.
Authors: B. B. Koolen, M. Donker, M. E. Straver, M. E. M. van der Noordaa, E. J. T. Rutgers, R. A. Valdés Olmos et al.
Notes: Reduced axillary lymph node dissection rates
Quality of life after mastectomy with or without immediate breast reconstruction. BJS 2017; 104: 1197-1206.
Authors: J. Dauplat, F. Kwiatkowski, P. Rouanet, E. Delay, K. Clough, J. L. Verhaeghe et al.
Notes: Good for the appropriate patient